Lv3
342 积分 2024-10-29 加入
CDK4/6 Inhibitors Increase PD-L1 Expression
1天前
已完结
Imbalanced GSH/ROS and sequential cell death
1天前
已完结
The feasibility of ROS- and GSH-responsive micelles for treating tumor-initiating and metastatic cancer stem cells
1天前
已完结
Glutathione and Reactive Oxygen Species Dual-Responsive Block Copolymer Prodrugs for Boosting Tumor Site-Specific Drug Release and Enhanced Antitumor Efficacy
1天前
已完结
Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib
2天前
已完结
Design, synthesis, and biological evaluation of novel CDK4/6 and BRD4 dual inhibitors for treatment of KRAS-mutant NSCLC
2天前
已完结
Discovery of Dual PD-L1/HDAC3 Inhibitors for Tumor Immunotherapy
2天前
已完结
Combination Approaches to Target PD-1 Signaling in Cancer
17天前
已完结
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
17天前
已完结
CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer
17天前
已完结
皖公网安备34019202002308
